The CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit is the first off-the-shelf reprogramming system designed for clinical and translational research. LikeRead more
Have Questions?
Catalog number A34546
Price (USD)
16,920.00
Each
Add to cart
Price (USD)
16,920.00
Each
Add to cart
The CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit is the first off-the-shelf reprogramming system designed for clinical and translational research. Like the CytoTune-iPS 2.0 Sendai reprogramming kit, this kit uses Sendai particles to deliver Yamanaka factors that are critical for efficient generation of induced pluripotent stem cells (iPSCs). This kit includes three vector preparations: polycistronic Klf4–Oct3/4–Sox2 (KOS), L-Myc, and Klf4.
Manufactured in accordance with GMP requirements This product is manufactured at a site with a process that was audited for conformity with current Good Manufacturing Practices for medical devices, 21 CFR Part 820 of the regulation.
Formulated animal origin–free The bovine serum albumin carrier protein was removed from the CTS CytoTune-iPS 2.1 Sendai vector formulation. The preparation contains no animal-derived components at the primary component level.
Accompanied by documentation to support your regulatory filing Full traceability documentation such as Certificate of Origin and Certificate of Analysis are available.
What you get The kit includes 0.2 mL of each vector (KOS, Klf4, and L-myc) at a titer of 0.5–2.0 x 108 CFU/mL, sufficient to reprogram a minimum of six wells of a six-well plate.
Specifications
Delivery TypeSendai
For Use With (Application)Cell and Gene Therapy Research, Development, and Manufacturing
Product LineCTS™
Product TypeiPSC Reprogramming Kit
Quantity1 kit
Shipping ConditionDry Ice
Shelf Life24 months from date of manufacture
Unit SizeEach
Contents & Storage
• 0.2 mL CTS CytoTune KOS • 0.2 mL CTS CytoTune Klf4 • 0.2 mL CTS CytoTune L-myc
Store at -70°C.
Frequently asked questions (FAQs)
What is CTS?
The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.
How many transductions can I perform with one CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit?
The CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit is sufficient to reprogram a minimum of six wells in a six-well plate. One well has a surface area of approximately 10 cm2.
Are the reprogramming steps in the CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit different compared to CytoTune-iPS 2.0 Sendai Reprogramming Kit?
No, the reprogramming steps are in principle the same but it is important to consider the difference in titer between the two kits when transducing cells at certain MOIs.
Why is the CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit so much more expensive than the CytoTune-iPS 2.0 Sendai Reprogramming Kit?
It is more expensive because of its label use statement: For research use and non-commercial manufacturing of cell based products for clinical research. CAUTION: Not intended for direct administration into animals or humans. The kit is manufactured according to GMP requirements and the drug master file is available for submission to FDA upon customer request, for use in clinical research.
Why does the CTS CytoTune-iPS 2.1 Sendai Reprogramming Kit contain L-Myc virus instead of c-Myc virus?
The L-Myc virus was chosen over the c-Myc virus because it is considered superior from a safety perspective, for clinical applications (L-myc is reported to have lower transformation/oncogenic potential than c-myc).